This category links to companies actively involved in research and development of their potential therapeutic products, derived from biological rather than chemical synthesis.
Related categories 1
Sites 19
- Arena Pharmaceuticals, Inc. Receptor-based drug discovery in the fields of diabetes, obesity, cardiovascular, sleep disorders, neurodegeneration, schizophrenia, depression and anxiety. Profile of company in San Diego, California. (Nasdaq: ARNA)
- BioSphings AG. Development and marketing of products to treat viral infections, cancer and autoimmune diseases. Features product pipeline and company details. Frankfurt, Germany.
- Curis, Inc Developing small molecule and peptide drugs in regulatory signaling and regenerative pathways. Introduces technical background, product pipeline, collaborations, investment data and careers headquartered from Cambridge, Massachusetts. (Nasdaq: CVGP)
- Cyano Biotech GmbH. Identifies and characterises structural variants of polyketides and non-ribosomal cyclic heptapeptides from cyanobacteria, and optimises pharmacological activity using biocombinatorial techniques. Profile, collaborators and contacts in Germany.
- Genentech, Inc. Development, production, and marketing of human therapeutics. Includes research history, product pipeline, global corporate and career information. San Francisco, California.
- Genfit Researching nuclear receptors and gene deregulation for treatment of cardiovascular, metabolic and inflammatory diseases. Includes information about genomic research headquartered in Loos, France.
- Imclone Systems Inc. Researches and develops growth factor blockers and anti-cancer vaccines. Includes clinical programs, investor details and overview of company in New York City. (Nasdaq: IMCL)
- Intra-Cellular Therapies, Inc. Developing novel drugs against targets inside nerve cells to treat CNS disorders. Includes therapeutic projects, target biochemistry, corporate data and contacts for headquarters in New York City.
- Nymox Pharmaceutical Corp. Researches and develops neurological diagnostics and pharmaceuticals for the aging population with emphasis on Alzheimer's disease. Profile of company with bases in Maywood, New Jersey and Saint Laurent, Quebec. (Nasdaq: NYMX)
- Sierra Sciences Inc. Developing drugs and therapies to reverse the effects of human aging by focusing on preserving the length of telomeres, to keep them more resilient. Careers in Reno, Nevada.
- Xoma Development and manufacture of recombinant proteins and peptides, in partnership with big pharmas. Includes licensing of technology derived from the host-defense protein BPI, monoclonal antibodies to treat chemotherapy-induced thrombocytopenia, and to target cancer. Based in Berkeley, California.
- Xencor, Inc. Technology for MHC epitope removal, glycosylation to optimize pharmacokinetics, masking immune recognition sites and engineering monoclonal antibodies. Includes discovery programs, partnering opportunities in Monrovia, California. ImmunoPDA Technology Product Sheet Caltech spin-off developing proteomic technologies to accelerate drug discovery.
- MannKind Corp. Developing a pulmonary insulin delivery system, and immunotherapy of cancer, by identifying tumor-related antigens, DNA and peptide-based drugs evoking cell-mediated responses. Located in Valencia, California.
- Trophogen, Inc Development of superactive hormones and growth factors for therapeutic applications. Based in Rockville, Maryland, USA.
- Optimer Pharmaceuticals Develops late-stage anti-infective and preclinical antibiotics by carbohydrate technology.
- Neurocrine Biosciences, Inc. Discovers and develops therapeutics for treatment of diseases and disorders of the central nervous and immune systems, including anxiety, depression, alzheimer's disease, obesity, stroke and multiple sclerosis. (Nasdaq: NBIX).
- Sequenom, Inc. Researches and develops high definition dna analysis tools for industrial biomedical and life science applications. (Nasdaq: SQNM).
- Can Fite BioPharma Ltd. Developer of anti-arthritis drug CF101 presents its management, technology, and research pipeline. Includes a list of publications and patents.
- SIGA Technologies Inc. Develops and commercializes vaccines, and novel antiviral therapeutics for category A pathogens, infectious diseases, and potential bio-defense. Laboratories in Corvallis, Oregon, headquartered in New York City. (Nasdaq: SIGA)